Loading...
XWARSVE
Market cap71mUSD
Dec 23, Last price  
4.14PLN
1D
-2.59%
1Q
-8.61%
Jan 2017
263.16%
IPO
-40.00%
Name

Biomed Lublin Wytwornia Surowic i Szczepionek SA

Chart & Performance

D1W1MN
XWAR:SVE chart
P/E
61.58
P/S
5.00
EPS
0.07
Div Yield, %
0.00%
Shrs. gr., 5y
3.02%
Rev. gr., 5y
12.66%
Revenues
59m
+16.32%
30,931,45239,142,85424,642,25232,976,98933,575,56642,587,72336,339,00031,404,00032,293,00039,107,00040,159,00041,154,00050,383,00058,607,000
Net income
5m
-21.76%
2,540,613524,59202,336,567163,2130-23,476,000588,000-32,412,0002,483,0004,439,0004,249,0006,081,0004,758,000
CFO
-5m
L
00000015,770,0004,356,000-620,0008,160,000343,000-3,281,0002,948,000-5,345,000

Profile

Synthaverse S.A., a pharmaceutical company, manufactures and sells medicinal products, medical devices, and laboratory reagents in Poland. The company's prescription drugs include Distreptaza, a medication used in gynecology for treating chronic inflammatory disease of the uterine appendages and hemorrhoids; Onko BCG 50 and BCG 100 products for treating superficial (non-muscle invasive) bladder tumor; GAMMA anty HBs 200 medications for passive immunization against hepatitis B; GAMMA anty-D 50 and GAMMA anty-D 150, which are Anti D (Rho) immunoglobulin products used in prevention of hemolytic disease of the foetus and newborn; BioTrombina 400, a medication for topical control of severe bleeding; and Anti-Tuberculosis Vaccine BCG 10, a medication used in tuberculosis prevention. It also offers medical products comprising Ram blood for laboratory use; stonebrink medium for biovine Mycobacterium tuberculosis diagnostics; Löwenstein-Jensen medium with medicines for testing medicine susceptibility of Mycobacterium tuberculosis; Löwenstein-Jensen medium containing glycerolfor is used for identification of Mycobacterium tuberculosis; Ox Thrombin for in-vitro diagnostics and Lyophilisate; and rabbit plasma. In addition, the company provides reagents, such as horse serum, bovine serum, calf serum, trypsin, PBS fluid, hanks fluid, parker's fluid, Eagle 1959 medium, Rpmi 1640 medium, and Ogawa medium, as well as pseudo cholinesterase, Ox fibrinogen, and rabbit complements. The company was formerly known as BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. and changed its name to Synthaverse S.A. in July 2023. The company was founded in 1944 and is based in Lublin, Poland.
URL
https://biomedlublin.com/
IPO date
Jul 29, 2011
Employees
Domiciled in
PL
Incorporated in
PL

Valuation

Title
PLN in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
58,607
16.32%
50,383
22.43%
41,154
2.48%
Cost of revenue
48,382
39,565
33,365
Unusual Expense (Income)
NOPBT
10,225
10,818
7,789
NOPBT Margin
17.45%
21.47%
18.93%
Operating Taxes
1,811
2,265
1,644
Tax Rate
17.71%
20.94%
21.11%
NOPAT
8,414
8,553
6,145
Net income
4,758
-21.76%
6,081
43.12%
4,249
-4.28%
Dividends
Dividend yield
Proceeds from repurchase of equity
620
25,414
34,053
BB yield
-0.21%
-6.49%
-12.15%
Debt
Debt current
8,840
7,147
3,763
Long-term debt
64,471
10,368
3,779
Deferred revenue
59,300
20,687
11,628
Other long-term liabilities
376
3,165
9,468
Net debt
64,117
(13,652)
(16,299)
Cash flow
Cash from operating activities
(5,345)
2,948
(3,281)
CAPEX
(112,601)
(36,755)
(18,428)
Cash from investing activities
(72,903)
(26,969)
(4,485)
Cash from financing activities
53,331
36,817
20,223
FCF
(132,627)
(23,693)
31,084
Balance
Cash
2,174
26,765
19,465
Long term investments
7,020
4,402
4,376
Excess cash
6,264
28,648
21,783
Stockholders' equity
(20,636)
(13,901)
(20,482)
Invested Capital
282,272
158,459
122,615
ROIC
3.82%
6.09%
5.70%
ROCE
3.89%
7.42%
7.53%
EV
Common stock shares outstanding
70,260
65,384
63,125
Price
4.27
-28.71%
5.99
34.91%
4.44
-50.45%
Market cap
300,012
-23.40%
391,648
39.74%
280,273
-49.76%
EV
364,129
377,996
263,974
EBITDA
16,855
17,038
14,333
EV/EBITDA
21.60
22.19
18.42
Interest
1,692
1,608
1,283
Interest/NOPBT
16.55%
14.86%
16.47%